AARD vs BIO · $284.4M cap vs rev $651.0M
Aardvark Therapeutics, Inc. Common Stock (AARD) versus BIO (BIO) — a side-by-side from cached financials, not a winner call.
Aardvark Therapeutics, Inc. Common Stock (AARD) is a biotechnology company listed on US.
BIO (BIO) common stock.
Latest reported AARD revenue for 2025-12-31 was $0. Net income was -$57.6M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AARD currently screens at market cap $284.4M.
Latest reported BIO revenue for 2026-06-30 was $651.0M. Net income was $371.4M. Revenue was up 9.9% from 2026-03-31 to 2026-06-30. BIO currently screens at market cap $0.
AARD currently screens at market cap $284.4M. BIO currently screens at market cap $0.
Not investment advice. Open the AARD and BIO stock pages for the full models.
Not investment advice.